Authors:
JD Bernstock, L Peruzzotti-Jametti, T Leonardi, N Vicario, D Ye, Y-J Lee, D Maric, KR Johnson, Y Mou, A Van Den Bosch, M Winterbone, GK Friedman, RJM Franklin, JM Hallenbeck, S Pluchino
Journal name: 
EBioMedicine
Abstract: 
BACKGROUND: Neural stem cell (NSC)-based therapies hold great promise for treating diseases of the central nervous system (CNS). However, several fundamental problems still need to be overcome to fully exploit the clinical potential of NSC therapeutics. Chief among them is the limited survival of NSC grafts within hostile microenvironments. METHODS: Herein, we sought to engineer NSCs in an effort to increase graft survival within ischemic brain lesions via upregulation of global SUMOylation, a post-translational modification critically involved in mediating tolerance to ischemia/reperfusion. FINDINGS: NSCs overexpressing the SUMO E2-conjugase Ubc9 displayed resistance to oxygen-glucose-deprivation/restoration of oxygen/glucose (OGD/ROG) and enhanced neuronal differentiation in vitro, as well as increased survival and neuronal differentiation when transplanted in mice with transient middle cerebral artery occlusion in vivo. INTERPRETATION: Our work highlights a critical role for SUMOylation in NSC biology and identifies a biological pathway that can be targeted to increase the effectiveness of exogenous stem cell medicines in ischemic stroke. FUND: Intramural Research Program of the NINDS/NIH, the Italian Multiple Sclerosis Foundation (FISM), the Bascule Charitable Trust, NIH-IRTA-OxCam and Wellcome Trust Research Training Fellowships.
DOI: 
http://doi.org/10.1016/j.ebiom.2019.03.035
E-pub date: 
28 Feb 2019
Users with this publication listed: 
Luca Peruzzotti-Jametti